Perceptive Advisors’s Cidara Therapeutics CDTX Stock Holding History

Perceptive Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-165,131	Closed	-$36.5M	–	104
2025 Q4	$36.5M	Buy	+165,131	New	+$26.7M	0.65%	42
2017 Q3	–	Sell	-3,106	Closed	-$465K	–	143
2017 Q2	$465K	Sell	3,106 -38,212	-92%	-$5.28M	0.02%	116
2017 Q1	$6.45M	Buy	41,318 +2,650	+7%	+$465K	0.37%	54
2016 Q4	$8.04M	Hold	38,668	–	–	0.57%	45
2016 Q3	$8.86M	Sell	38,668 -975	-2%	-$225K	0.57%	43
2016 Q2	$8.17M	Buy	39,643 +2,500	+7%	+$605K	0.57%	42
2016 Q1	$9.43M	Hold	37,143	–	–	0.83%	29
2015 Q4	$12.7M	Hold	37,143	–	–	0.94%	29
2015 Q3	$9.45M	Buy	37,143 +22,143	+148%	+$6.33M	0.75%	33
2015 Q2	$4.21M	Buy	+15,000	New	+$4.61M	0.25%	73

Perceptive Advisors's CDTX Position: Q1 2026 in Review

Perceptive Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 165,131 shares — an estimated $36.5M sold.

Perceptive Advisors first reported a position in CDTX in Q2 2015 and held it in 10 quarters. The position peaked at $36.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Perceptive Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Perceptive Advisors sold 165,131 Cidara Therapeutics shares in Q1 2026, an estimated $36.5M.
Perceptive Advisors first reported a position in Cidara Therapeutics in Q2 2015 and held it in 10 quarters.
Perceptive Advisors's Cidara Therapeutics position peaked at $36.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.